Clinical trials
HER2-negative Breast Cancer clinical trials
Below are recruiting her2-negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 265 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT06993506Recruiting
SKB264 alone or combined for advanced HER2- breast cancer
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
Hefei, AnhuiAges 18 years+ - NCT06967103RecruitingPhase 2
New drug before breast cancer surgery
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
ZhengzhouAges 18 years+ - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06953882RecruitingPhase 2
Skipping chemo after surgery for ER+ HER2- breast cancer
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT06946238Recruiting
Single-dose radiation after surgery for low-risk breast cancer
This trial tests giving a single, very targeted dose of radiation right after surgery for early-stage breast cancer. It is for women age 40+ with small, low-risk tumors (Luminal A or B) that have been fully removed and have not spread to lymph nodes.
MilanAges 40 years+ - NCT06942234RecruitingPhase 1/Phase 2
Study of JSKN016 for advanced HER2-negative breast cancer
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
ShanghaiAges 18–75 - NCT06931769Recruiting
Optimizing treatment for stage III triple-negative breast cancer
This trial studies the best ways to give chemotherapy before and after surgery for stage III triple-negative breast cancer. It aims to improve treatment outcomes by using a personalized approach and patient-reported data.
Enschede, OverijsselAges 18 years+ - NCT06930859Recruiting
Study of Ribociclib for HR+ HER2-negative breast cancer in Russia
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
Sochi, Russian FederationAges 18–99 - NCT06914440RecruitingPhase 2
Radiation and immunotherapy before surgery for HR+/HER2- breast cancer
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Xi'an, Shannxi ProvinceAges 18–75 - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06905301Recruiting
Study on breast cancer medication with a mobile app
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
Pskov, RussiaAges 18–90 - NCT06908668RecruitingPhase 2
Adebrelimab plus chemo with or without radiation before breast cancer surgery
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
BeijingAges 18–70 - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06860529RecruitingPhase 2
Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Zhengzhou, HenanAges 18 years+ - NCT06867484Recruiting
Breast re-irradiation after second lumpectomy
This trial tests whether giving a second round of radiation to the breast after a lumpectomy for a recurrence is safe and effective. It is for people with a specific type of breast cancer (ER+HER2-) who meet strict criteria regarding prior radiation and tumor characteristics.
Boca Raton, FloridaAges 40 years+ - NCT05396612Recruiting
Studying the immune response in non-cancer-spread breast surgery
This study looks at how your immune system changes while you receive standard breast cancer treatment around the time of surgery. The goal is to learn why some people respond better than others, which could help future treatment choices.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06845319RecruitingPhase 2
Chemo-immunotherapy before surgery for triple-negative breast cancer
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Charleston, South CarolinaAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06807749Recruiting
Adjuvant treatment for premenopausal breast cancer
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
Roma, Antonella PalazzoAges Up to 60 years
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-negative breast cancer?
- Yes. Clin2 currently lists 265 recruiting her2-negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Metastatic Breast Cancer ( HER2 Negative)
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- HR+/HER2- Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.